AstraZeneca Year-to-date and Q3 2015 Results

AstraZeneca will announce its results for year-to-date and Q3 2015 on Thursday 5 November 2015 with a scheduled Stock Exchange release time of 07:00GMT (08:00CET, 02:00amEST). The announcement will also be available at An accompanying conference call will take place at 12:00GMT (13:00CET, 07:00AM EST) and will be accessible via two routes:

1. Audio webcast

Listeners will be able to pre-register and test the webcast via from Monday 2 November. During the Q&A session listeners will be able to pose questions to the presenters via e-mail. If you wish to participate in the Q&A session live rather than by e-mail you will need to dial into the conference call; details are shown below.

An indexed version of the webcast will be available from 17:30GMT on Thursday 5 November2015 on

2. Conference call

If you wish to listen to the presentation and take part in the Q&A session live, please see the details below:

UK (freephone): 0800 694 2370
International: +44 1452 557749
Sweden (freephone): 0200 883 079
USA (freephone): 866 977 7645

Conference ID: 75218823

To ensure that you don’t miss the start of the conference call please dial into the call five minutes early. The presentation will be available for download on the AstraZeneca Investor Relations website 30 minutes before the conference call begins.

American Society of Clinical Oncology (ASCO) Annual Meeting

1 June 2015

AstraZeneca will be hosting a briefing for analysts and investors during the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago on Monday 1 June 2015, from 8:30pm –10:00pm CDT (2 June 2:30am - 4:00am BST – UK). The aim of this event is to update on progress with AstraZeneca’s immuno-oncology pipeline and combination treatments.

You will be able to listen to the event using the following dial in details:

UK freephone: 0800 694 0257
US freephone: 866 966 9439
Sweden freephone: 0200 890171
International: +44 (0) 1452 555566

Conference code: 42762226

Listen to webcast

Latest downloads

ASCO 2015 Investor science event

1 June 2015

ASCO 2015 Investor science event biographies

1 June 2015

AstraZeneca Mölndal

22 May 2015

First quarter results 2015

24 April 2015

Investor science conference call ACC 2015

16 March 2015

AstraZeneca refines its financial reporting in line with evolving business model

6 March 2015

Investor Relations presentation - March 2015

5 March 2015

Fourth quarter and full year results 2014

5 February 2015

Latest press releases

New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
30 September 2015
AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)
24 September 2015
AstraZeneca to present data demonstrating diversity of its portfolio of innovative formulations and devices at the European Respiratory Society International Congress 2015
22 September 2015
AstraZeneca presents positive pooled analysis demonstrating the effect of dapagliflozin on albuminuria in hypertensive patients with type 2 diabetes
17 September 2015
AstraZeneca announces new tolerability, long-term efficacy and real-world adherence data for exenatide once weekly in patients with type 2 diabetes
15 September 2015
AstraZeneca to present comprehensive data from its diabetes portfolio and pre-clinical research at EASD 2015
11 September 2015
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline
11 September 2015
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester
8 September 2015
AstraZeneca to update on leading lung cancer portfolio at WCLC 2015
4 September 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
3 September 2015
Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
2 September 2015
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
2 September 2015

Share price

41.38 GBP
New York
31.30 USD
514.50 SEK

At 13-10-2015 23:54 GMT

Detailed share price

Stock symbol - AZN